CD33 Radioconjugates for MDSC Depletion in Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers and proliferative disorders, particularly those involving myeloid-derived suppressor cells (MDSCs) and solid tumors, are inadequate in effectively targeting and eliminating CD33-positive cells, leading to immunosuppression and immunological escape.
Innovation Solution
The use of radioconjugates, such as Actinium-225 labeled monoclonal antibodies against CD33, in combination with other cancer-associated targets like DR5, 5T4, HER2, and HER3, along with antibody drug conjugates and immune checkpoint inhibitors, to selectively target and eliminate MDSCs and other cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for cancers involving MDSCs and solid tumors, then treatment coverage is broad, but effectiveness in targeting and eliminating CD33-positive cells is insufficient
Solution Approach 1:
The patent introduces radioconjugates as intermediary agents that specifically bind to CD33-positive cells (MDSCs and solid tumors). These radioconjugates consist of a targeting moiety (antibody or ligand) that recognizes CD33 and a radioactive isotope that delivers cytotoxic radiation, thereby mediating selective elimination of target cells while sparing non-target tissues.
Solution Approach 2:
The patent applies local quality by concentrating the cytotoxic effect precisely at the site of CD33-positive cells through targeted radioconjugate binding. The radioactive isotopes deliver high-dose radiation locally to tumor cells and MDSCs expressing CD33, while surrounding healthy tissues receive minimal radiation exposure, thus achieving both high effectiveness and selectivity.
2Reliability
If radioconjugates targeting CD33 are used, then selectivity for CD33-positive cells is improved, but treatment complexity increases
Solution Approach 1:
The patent employs radioconjugates with dual functionality: the targeting moiety provides specific binding to CD33-positive cells, while the radioactive isotope delivers cytotoxic radiation. This multi-functional design consolidates targeting and therapeutic functions into a single agent, simplifying the overall treatment approach despite the sophistication of the mechanism.
Solution Approach 2:
The radioconjugates exhibit self-service characteristics by autonomously navigating to CD33-positive cells through specific binding and delivering their cytotoxic payload without requiring external guidance or complex delivery systems. The radioactive decay process occurs spontaneously within the bound radioconjugate, eliminating the need for complex external activation mechanisms.
3Reliability
If combination therapy with multiple targets is implemented, then treatment efficacy is enhanced, but treatment protocol complexity increases
Solution Approach 1:
The patent merges multiple therapeutic approaches into a unified combination regimen that includes radioconjugates targeting CD33, radioconjugates targeting other cancer-associated antigens (such as DR5, 5T4, HER2, HER3), antibody-drug conjugates, chemotherapy, and immune checkpoint inhibitors. This integrated approach synergistically enhances treatment efficacy by attacking cancer through multiple mechanisms simultaneously.
Solution Approach 2:
The patent segments the combination therapy into distinct modular components, each targeting specific aspects of cancer biology: CD33-targeted radioconjugates for MDSC and solid tumor elimination, other targeted radioconjugates for additional antigen coverage, antibody-drug conjugates for cytotoxic delivery, chemotherapy for broad antiproliferative activity, and immune checkpoint inhibitors for immune system activation. This modular segmentation allows for flexible customization and systematic management of the complex regimen.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively depletes MDSCs and other cancer cells, enhancing the immune response against tumors and improving treatment outcomes for both hematological and solid tumor cancers.
Implementation Method 1
Actinium-225 labeled monoclonal antibodies against CD33
Data Source
AI summary
The invention provides compositions and methods for treating cancers and proliferative disorders, including solid tumor cancers and non-myeloid hematological malignancies, using radioconjugates targeting CD33, alone or in combination with one or more radioconjugates targeting other cancer-associated targets such as DR5, 5T4, HER2, HER3, and TROP2, antibody drug conjugates targeting these or other cancer-associated targets, therapeutic antibodies targeting these or other cancer-associated targets, chemotherapy agents and regimens, and immune checkpoint inhibitors.